Condition

Recurrent Kaposi Sarcoma

ClinicalTrials.gov condition label

Clinical trials6

Recruiting1

Common interventions13

Lead sponsors shown2

Clinical trials

6 shown

Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related CancersNCT05663502 · 2023-05-10

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVNCT04514484 · 2021-11-22

ACTIVE_NOT_RECRUITING

Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi SarcomaNCT02137564 · 2015-07-01

Lenalidomide in Treating Patients With AIDS-Associated Kaposi's SarcomaNCT01057121 · 2010-08-27

Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi SarcomaNCT01016730 · 2010-01-22

Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's SarcomaNCT00064142 · 2003-05-01

Common interventions

laboratory biomarker analysisOTHER3 Biospecimen CollectionPROCEDURE2 pharmacological studyOTHER2 BortezomibDRUG1 Cabozantinib S-malateDRUG1 Computed TomographyPROCEDURE1 gamma secretase inhibitor PF-03084014DRUG1 halofuginone hydrobromideDRUG1 LenalidomideDRUG1 Magnetic Resonance ImagingPROCEDURE1 NivolumabBIOLOGICAL1 placeboOTHER1 Questionnaire AdministrationOTHER1

Leading sponsors

National Cancer Institute (NCI)4 AIDS Malignancy Consortium2

Trial status mix

COMPLETED3

ACTIVE_NOT_RECRUITING1

RECRUITING1

WITHDRAWN1

Phase mix

PHASE13

PHASE23

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.